RETRACTED: Low density lipoprotein receptor targeted doxorubicin/DNA-Gold Nanorods as a chemo- and thermo-dual therapy for prostate cancer.
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal).

This article has been retracted at the request of the authors and sanctioned by the Editor-in-Chief.

The authors found errors in the data presentation - apoptotic statistics and in vivo distribution - which makes the conclusion not representative. The authors express sincere apologies for the error and inconvenience to readers.
Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, HeNan 450001, PR China.
Nan
N
Zhang
Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, HeNan 450001, PR China.
Shasha
S
Li
Academy of Medical and Pharmaceutical Sciences of Zhengzhou University, Zhengzhou, HeNan 450052, PR China.
Haiying
H
Hua
Academy of Medical and Pharmaceutical Sciences of Zhengzhou University, Zhengzhou, HeNan 450052, PR China.
Dan
D
Liu
Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, HeNan 450001, PR China.
Lili
L
Song
Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, HeNan 450001, PR China.
Pengchao
P
Sun
Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, HeNan 450001, PR China.
Weiwei
W
Huang
Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, HeNan 450001, PR China.
Yafang
Y
Tang
Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, HeNan 450001, PR China. Electronic address: zhaoyx@zzu.edu.cn.
Yongxing
Y
Zhao
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003131:Combined Modality Therapy; D018736:DNA Adducts / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D004337:Drug Carriers / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D006046:Gold / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D043942:Nanotubes / Q000737:chemistry; D010455:Peptides / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D011973:Receptors, LDL / Q000378:metabolism*; D047368:Tumor Burden / Q000187:drug effects
D000970:Antineoplastic Agents; D018736:DNA Adducts; D004337:Drug Carriers; D010455:Peptides; C000607513:RLT peptide; D011973:Receptors, LDL; C031902:doxorubicin-DNA; D011092:Polyethylene Glycols; D006046:Gold; D004317:Doxorubicin
Chemotherapy; Doxorubicin; Gold nanorods; Low density lipoprotein peptide; Prostate cancer; Thermotherapy